

**Enhanced  
global strategy  
for further  
reducing the  
disease burden  
due to leprosy**

**Questions and answers**

# Enhanced global strategy for further reducing the disease burden due to leprosy

## Questions and answers

**© World Health Organization 2012**

All rights reserved.

Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – can be obtained from Publishing and Sales, World Health Organization, Regional Office for South- East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11 23370197; e-mail: publications@searo.who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in India

# CONTENTS

FOREWORD.....	XI
STRATEGIC ISSUES.....	1
Q 1: HOW HAS THE CURRENT GLOBAL STRATEGY FOR LEPROSY BEEN DEVELOPED?	1
Q 2: WHAT OTHER ISSUES ARE ADDRESSED IN THE CURRENT STRATEGY?	2
Q 3: WHAT ELEMENTS OF LEPROSY CONTROL WILL BE ENHANCED DURING THE IMPLEMENTATION OF THE CURRENT STRATEGY?	2
Q 4: WHAT HAS BEEN ACHIEVED SINCE THE INTRODUCTION OF MDT?	3
Q 5: WHAT ARE THE REMAINING CHALLENGES FACED BY THE PROGRAMMES IN ENDEMIC COUNTRIES?	3
Q 6: WHAT IS MEANT BY THE DISEASE BURDEN DUE TO LEPROSY?	4
Q 7: WHAT IS THE CURRENT TARGET SET FOR LEPROSY CONTROL PROGRAMMES?	4
INTEGRATING LEPROSY INTO GENERAL HEALTH SERVICES.....	6
Q 8: WHY IS IT CRUCIAL TO INTEGRATE LEPROSY WITHIN THE GENERAL HEALTH SERVICES?	6
Q 9: WHAT ARE THE BASIC REQUIREMENTS FOR INTEGRATION IN THE FIELD?	7
Q 10: WHAT IS MEANT BY EASY ACCESS TO MDT SERVICES AND WHY IS IT IMPORTANT?	7
Q 11: WHAT TYPE OF TRAINING SHOULD BE PROVIDED TO GENERAL HEALTH WORKERS?	8
Q 12: IS THERE ANY ROLE FOR SPECIALIZED/VERTICAL ELEMENTS IN AN INTEGRATED PROGRAMME?	8

<b>COMMUNITY AWARENESS AND PARTICIPATION .....</b>	<b>9</b>
Q 13: WHY DO WE NEED TO CHANGE THE IMAGE OF LEPROSY?	9
Q 14: WHAT ARE THE MOST IMPORTANT MESSAGES ABOUT LEPROSY FOR THE COMMUNITY?	10
Q 15: WHAT ARE THE KEY CHANNELS FOR AN EFFECTIVE COMMUNICATION CAMPAIGN?	10
Q 16: WHEN SHOULD THE COMMUNICATION CAMPAIGNS BE LAUNCHED?	11
Q 17: WHY SHOULD COMMUNITIES BE ACTIVELY INVOLVED IN LEPROSY CONTROL ACTIVITIES?	12
Q 18: HOW CAN COMMUNITY AWARENESS AND INVOLVEMENT IN THE PROGRAMME BE IMPROVED?	12
Q 19: HOW DO INFORMATION, EDUCATION AND COMMUNICATION ACTIVITIES ASSIST IN LEPROSY CONTROL PROGRAMMES?	13
<b>URBAN AREAS .....</b>	<b>14</b>
Q 20: HOW CAN THE PROGRAMME IMPROVE ACCESS TO LEPROSY SERVICES IN URBAN AREAS?	14
<b>GENDER ISSUE.....</b>	<b>15</b>
Q 21: DOES LEPROSY AFFECT WOMEN MORE THAN MEN?	15
<b>ROLE OF PEOPLE AFFECTED BY LEPROSY.....</b>	<b>16</b>
Q 22: IS THERE A NEED TO INVOLVE PERSONS AFFECTED BY LEPROSY IN LEPROSY CONTROL ACTIVITIES?	16
<b>REFERRAL SYSTEM.....</b>	<b>17</b>
Q 23: HOW CAN REFERRAL SYSTEMS BE STRENGTHENED?	17
Q 24: HOW CAN LEPROSY EXPERTISE BE MAINTAINED WHEN THE DISEASE BURDEN DECLINES?	17
Q 25: WHICH CONDITIONS IN LEPROSY REQUIRE REFERRAL?	18

<b>DISEASE PREVENTION .....</b>	<b>19</b>
Q 26: HOW EFFECTIVE IS THE PRIMARY BCG IMMUNIZATION IN PREVENTING LEPROSY?	19
Q 27: CAN ANY ANTILEPROSY DRUG BE USED FOR CHEMOPROPHYLAXIS?	19
Q 28: CAN LEPROSY BE PREVENTED AMONG HOUSEHOLD CONTACTS?	20
<b>PREVENTION OF DISABILITIES AND REHABILITATION.....</b>	<b>21</b>
Q 29: HOW MANY PEOPLE SUFFER FROM IMPAIRMENTS AND DISABILITIES DUE TO LEPROSY?	21
Q 30: HOW CAN IMPAIRMENT AND DISABILITIES BE PREVENTED IN LEPROSY?	21
Q 31: WHAT IS SELF-CARE?	22
Q 32: WHAT IS COMMUNITY-BASED REHABILITATION IN LEPROSY?	22
Q 33: WHAT CAN BE DONE WITH THE RESIDENTIAL CARE INSTITUTIONS FOR LEPROSY-AFFECTED PEOPLE THAT ARE STILL ACTIVE IN MANY ENDEMIC COUNTRIES?	22
<b>EPIDEMIOLOGICAL ISSUES.....</b>	<b>23</b>
Q 34: WHAT ARE THE DIFFERENCES BETWEEN DISEASE CONTROL, ELIMINATION AND ERADICATION?	23
Q 35: WHERE DID LEPROSY ORIGINATE?	24
Q 36: WHAT IS THE CAUSATIVE AGENT OF LEPROSY?	24
Q 37: HOW IS LEPROSY TRANSMITTED?	25
Q 38: HOW INFECTIOUS IS LEPROSY?	25
Q 39: WHAT ARE THE RISK FACTORS FOR CONTRACTING LEPROSY?	25
Q 40: HAS THE HIV PANDEMIC AFFECTED LEPROSY IN THE SAME WAY AS TUBERCULOSIS?	26
Q 41: WHAT IS THE IMPORTANCE OF CONTACT SURVEILLANCE?	26
Q 42: WHY IS THE DECLINE IN INCIDENCE IN LEPROSY SLOWER THAN THE DECLINES OBSERVED IN PREVALENCE?	26

Q 43: WHAT IS EXPECTED FROM STUDIES ON THE <i>MYCOBACTERIUM LEPRAE</i> GENOME?	27
<b>CURRENT GLOBAL SITUATION</b> .....	<b>28</b>
Q 44: IS LEPROSY STILL ENDEMIC IN MANY COUNTRIES?	28
Q 45: WHAT IS THE CURRENT LEPROSY SITUATION IN THE WORLD?	28
<b>DIAGNOSIS AND CASE MANAGEMENT</b> .....	<b>29</b>
Q 46: WHEN SHOULD LEPROSY BE SUSPECTED?	29
Q 47: HOW IS THE DIAGNOSIS OF LEPROSY CONFIRMED?	29
Q 48: HOW IS LEPROSY CLASSIFIED?	30
Q 49: WHAT CLASSIFICATION IS USED TO DECIDE THE TREATMENT REGIMEN FOR A PATIENT IN THE FIELD?	30
<b>MULTIDRUG THERAPY</b> .....	<b>31</b>
Q 50: WHAT WAS THE GUIDING PRINCIPLE IN THE DEVELOPMENT OF MDT?	31
Q 51: WHAT ARE THE RECOMMENDED STANDARD TREATMENT REGIMENS FOR LEPROSY?	31
Q 52: WHAT IS THE EVIDENCE THAT MDT IS EFFECTIVE IN MB AND PB LEPROSY?	32
Q 53: IS THERE ANY EVIDENCE THAT THE DRUGS INCLUDED IN MDT CAN ANTAGONIZE EACH OTHER'S ANTIBACTERIAL ACTIVITY?	33
Q 54: DOES MDT HELP IN REDUCING THE FREQUENCY AND SEVERITY OF LEPROSY REACTIONS?	33
Q 55: WHY IS RIFAMPICIN GIVEN ONLY ONCE A MONTH?	33
Q 56: WHY IS CLOFAZIMINE GIVEN ONCE A MONTH IN ADDITION TO THE DAILY DOSE?	33
Q 57: CAN MDT PREVENT THE DEVELOPMENT OF RESISTANCE OF <i>M. LEPRAE</i> TO ANTILEPROSY DRUGS?	34
Q 58: WHY IS SURVEILLANCE OF DRUG RESISTANCE IN LEPROSY IMPORTANT?	34
Q 59: CAN MDT ELIMINATE PERSISTING <i>M. LEPRAE</i> ?	34

Q 60: WHAT ARE THE COMMON ADVERSE DRUG REACTIONS REPORTED WITH MDT?	35
Q 61: IS MDT CONTRAINDICATED IN PATIENTS SUFFERING FROM TUBERCULOSIS?	35
Q 62: IS MDT CONTRAINDICATED IN PATIENTS SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION?	35
Q 63: IS MDT SAFE DURING PREGNANCY AND LACTATION?	36
Q 64: HOW LONG DOES IT TAKE FOR SKIN DISCOLOURATION CAUSED BY CLOFAZIMINE TO DISAPPEAR?	36
Q 65: WHY IS MDT CONSIDERED TO BE ONE OF THE MOST EFFECTIVE AND COST-EFFECTIVE INTERVENTIONS IN PUBLIC HEALTH?	36
Q 66: HOW CAN MDT BE PROVIDED IN A PATIENT-FRIENDLY AND FLEXIBLE MANNER?	37
Q 67: WHAT ARE THE AVAILABLE SECOND-LINE ANTILEPROSY DRUGS?	37
Q 68: WHAT ARE THE OTHER ANTILEPROSY DRUGS UNDER DEVELOPMENT?	37
Q 69: WHAT ARE THE TREATMENT REGIMENS FOR PATIENTS WHO CANNOT TAKE ANY OF THE DRUGS IN MULTIDRUG THERAPY?	38
Q 70: WHAT TYPES OF PATIENTS ARE AT RISK OF DEVELOPING RELAPSE AFTER MDT?	39

预览已结束，完整报告

<https://www.yunbaogao.cn/report/inc>